

Index

24-hour ambulatory pH-metry, 761

- Abate, M.L. *see* Gaia, S.
 Abenavoli, L. *see* Addolorato, G.
 Abenavoli, L. *see* Leggio, L.
 absenteeism and presenteeism, 459
 acceptability, 657
 acetaminophen, 29
 achalasia, 431
 Achkar, J.P. *see* Stevens, T.
 acid suppression, 195, 423
 acid, 517, 975
 Ackroyd, R. *see* Kelty, C.J.
 actigraphy, 969
 acupuncture, 831
 acute hepatitis C, 15
 Adachi, K. *see* Amano, Y.
 Adachi, K. *see* Fujisawa, T.
 Adam, V. *see* Barkun, A.N.
 Addolorato, G. *see* Leggio, L.
 Addolorato, G., De Lorenzi, G., Abenavoli, L., Leggio, L., Capristo, E. & Gasbarrini, G. Psychological support counselling improves gluten-free diet compliance in coeliac patients with affective disorders, 777
 adefovir, 993
 adenocarcinoma, 1125
 ADHD, 109
 adherence, 1071
 adolescents, 295
 adverse effects, 917
 adverse events, 859, 1071
 Aeed, H. *see* Levine, A.
 aetiology, 1195
 Afzal, N.A., van der Zaag-Loonen, H.J., Arnaud-Battandier, F., Davies, S., Murch, S., Derkx, B., Heuschkel, R. & Fell, J.M. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition, 167
 age, 697, 1053
 Agrawal, N. *see* Goldstein, J.L.
 Ahlbom, H. *see* Wilder-Smith, C.H.
 Alain, S. *see* De Saussure, P.
 alarm symptoms, 1045
 alcoholic liver cirrhosis, 437
 almagate, 683
 alosetron, 223
 Amano, Y., Ishihara, S., Kushiya, Y., Yuki, T., Takahashi, Y., Chinuki, D., Miyake, T., Miyaoka, Y., Rumi, M.A.K., Ishimura, N., Adachi, K. & Kinoshita, Y. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage, 793
 aminosaliclates, 143, 151
 amitriptyline, 689
 amylase, 173
 anaemia, 917
 Anderloni, A. *see* Parente, F.
 Anderson, M. *see* Tsai, H.H.
 Andersson, T. *see* Katz, P.O.
 Andriulli, A. *see* Annese, V.
 Andriulli, A. *see* Pilotto, A.
 anicteric, 15
 Annese, V., Piepoli, A., Perri, F., Lombardi, G., Latiano, A., Napolitano, G., Corritore, G., Vandewalle, P., Poulain, D., Colombel, J.F. & Andriulli, A. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features, 1143
 Annicchiarico, B.E. & Siciliano, M. Pegylated interferon- α 2b monotherapy for haemodialysis patients with chronic hepatitis C, 123
 anorectal and behavioral therapy, 667
 antibiotics, 1181
 antimicrobials, 675
 anti-Saccharomyces cerevisiae antibodies (ASCA), 1143
 antisecretory agents, 321
 antisecretory drugs, 683
 anti-ulcer medication, 577
 antiviral therapy, 931
 anxiety and depression, 803
 anxiety, 89
 apoptosis, 793
 Arakawa, Y. *see* Kato, K.
 Armstrong, D. *see* Bardhan, K.D.
 Armstrong, D. *see* Fallone, C.A.
 Armstrong, D., Talley, N.J., Lauritsen, K., Moum, B., Lind, T., Tunturi-Hihnal, H., Venables, T., Green, J., Bigard, M.A., Mössner, J. & Junghard, O. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole, 413
 Arnaud-Battandier, F. *see* Afzal, N.A.
 arousals, 1153
 ascites, 271
 Aspinall, R.J. & Pockros, P.J. Review article: the management of side-effects during therapy for hepatitis C, 917
 aspirin, 645, 1091
 assessment, 89
 Attwell, A., Ludkowski, M., Nash, R. & Kugelmas, M. Treatment of Budd-Chiari syndrome in a Liver Transplant Unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation, 867

- Austin, P. *see* Fallone, C.A.
 autoantibodies, 129, 231
 autoimmunity, 129
 Avigan, M. *see* Brinker, A.
 Avni, Y. *see* Levine, A.
 azathioprine, 65, 143, 151, 161, 843
 azithromycin, 295
 Azumi, T. *see* Fujisawa, T.
- Bacillus clausii*, 1181
 Badiola, C. *see* Rey, E.
 Bajaj, J.S. *see* Saeian, K.
 Balaguer, F. *see* Mata, A.
 balloon size, 431
 Barbon, V. *see* Gaia, S.
 Barcak, E. *see* Kulkarni, K.
 Bardhan, K.D., Forbes, A., Marsden, C.L., Mason, T. & Short, G.
 The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study, 213
 Bardhan, K.D., Stanghellini, V., Armstrong, D., Berghöfer, P., Gatz, G. & Mönnikes, H. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease, 891
 Bardou, M. *see* Barkun, A.N.
 Barkun, A.N. *see* Fallone, C.A.
 Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. & Bardou, M. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding, 195
 barostat, 689, 975
 Barrado, A. *see* Salgueiro, J.
 Barrett's epithelium, 793
 Barrett's oesophagus, 637, 645, 705, 719, 1083, 1125
 Barril, G., Quiroga, J.A., Sanz, P., Rodríguez-Salván, F., Selgas, R. & Carreño, V. Pegylated interferon- α 2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers, 37
 Barth, J. *see* Vakil, N.
 basic Fibroblast Growth Factor (bFGF), 585
 Bastens, B. *see* Delwaide, J.
 Bastida, G. *see* Domènech, E.
 Bathgate, A.J. *see* Younger, H.M.
 Bebb, J.R. & Scott, B.B. Systematic review: how effective are the usual treatments for ulcerative colitis? 143, 151
 Beck, A. *see* Delvaux, M.
 Beglinger, C. *see* Lesbros-Pantolickova, D.
 Behrens, C. *see* Raedler, A.
 Belaiche, J. *see* Franchimont, N.
 Bellissant, E. *see* Siproudhis, L.
 Bengtsson, C. *see* Tindberg, Y.
 van den Berg, A.P. *see* Weersma, R.K.
 Berghöfer, P. *see* Bardhan, K.D.
 Bergmans, P. *see* de Wit, N.J.
 Berman, B. *see* Sung, J.J.Y.
 Bermejo, F. *see* Lopez-Sanroman, A.
 Bernabucci, V. *see* Gatta, L.
 Betterle, C. *see* Briani, C.
- Bharucha, A.E., Locke III, G.R., Seide, B.M. & Zinsmeister, A.R. A new questionnaire for constipation and faecal incontinence, 355
 Bianchi Porro, G. *see* Parente, F.
 Bias, P. *see* Raedler, A.
 Bicheler, V. *see* Bruley des Varannes, S.
 bifidobacteria, 1133
 Bigard, M.A. *see* Armstrong, D.
 bioequivalence, 407
 biofeedback, 539, 667
 Birani, C. Reply, 821
 Bishehsari, F. *see* Mikaeli, J.
 Blacka, J., Donoghue, J., Sutherland, M., Martincich, I., Mitten-Lewis, S., Morris, P. & Meredith, G. Dwell time and functional failure in percutaneous endoscopic gastrostomy tubes: a prospective randomized-controlled comparison between silicon polymer and polyurethane percutaneous endoscopic gastrostomy tubes, 875
 Blennow, M. *see* Tindberg, Y.
 blood flow, 517
 Blum, A.L. *see* Bytzer, P.
 Blum, A.L. *see* Lesbros-Pantolickova, D.
 BMI, 223
 Boaz, M. *see* Levine, A.
 Boccio, J. *see* Salgueiro, J.
 Bochenek, W. *see* Richter, J.E.
 Bochenek, W.J., Mack, M.E., Fraga, P.D. & Metz, D.C. Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis, 1105
 body mass index, 497
 de Boer, W.A. *see* de Wit, N.J.
 Bolus, R. *see* Labus, J.S.
 Bonaz, B. *see* Bruley des Varannes, S.
 Bondarov, P. *see* Wilder-Smith, C.H.
 bone metabolism, 607
 Bonnot-Marlier, S. *see* Bruley des Varannes, S.
 Boparai, V. *see* Gerson, L.B.
 Bordas, J.M. *see* Mata, A.
 Borgia, M.C. *see* Consolazio, A.
 Bost, R. *see* Bruley des Varannes, S.
 Bott, C., Rudolph, M.W., Schneider, A.R.J., Schirmacher, S., Skalsky, B., Petereit, H.-U., Langguth, P., Dressman, J.B. & Stein, J. *In vivo* evaluation of a novel pH- and time-based multiunit colonic drug delivery system, 347
 Bouhnik, Y. *see* de Saussure, P.
 Boulton-Jones, J.R., Fenn, R.M.F., West, J., Logan, R.F.A. & Ryder, S.D. Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls, 551
 Bourgeois, N. *see* Delwaide, J.
 Bouzamondo, H. *see* Delvaux, M.
 Bovenschen, H.J., Laheij, R.J.F., Tan, A.C.I.T.L., Witteman, E.M., van Rossum, L.G.M. & Jansen, J.B.M.J. Health-related quality of life of patients with gastrointestinal symptoms, 311
 bowel ultrasound, 959
 bowel wall behaviour, 959
 Bracco, A. *see* Reilly, M.C.
 Braden, B. *see* Kerber, A.
 breakthrough, 281

- breath tests*, 347
- Briani, C., Ruggero, S., Zara, G., Toffanin, E., Ermani, M., Betterle, C. & Guariso, G. Anti-ganglioside antibodies in children with coeliac disease: correlation with gluten-free diet and neurological complications, 231
- Brignoli, R. *see* Melzer, J.
- Brinker, A. & Avigan, M. Epidemiology of ischaemic colitis, 697
- Brisinda, G., Cadeddu, F., Mabisombi, A. & Maria, G. Author's reply, 123
- Brown, G.R. *see* Getachew, Y.
- Brown, N.J. *see* Kelty, C.J.
- Browning, J.D. *see* Getachew, Y.
- Bruley des Varannes, S., Gharib, H., Bicheler, V., Bost, R., Bonaz, B., Stanescu, L., Delchier, J.C. & Bonnot-Marlier, S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects, 899
- Bruzzese, E., Raia, V., Gaudiello, G., Polito, G., Buccigrossi, V., Formicola, V. & Guarino, A. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration, 813
- Brzezinski, A. *see* Stevens, T.
- Buccigrossi, V. *see* Bruzzese, E.
- Budd-Chiari syndrome, 867
- budesonide, 745
- Buell, D. *see* Pettengell, K.
- Bunnapradist, S. *see* Fabrizi, F.
- Buss, D.C. *see* Ingram, J.R.
- butyrate, 1133
- Bytzer, P. *see* Madsen, L.G.
- Bytzer, P., Blum, A., De Herdt, D., Dubois, D. & on behalf of the trial investigators Six-month trial of on-demand rabeprazole 10mg maintains symptom relief in patients with non-erosive reflux disease, 181
- Bytzer, P. & Blum, A.L. Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease, 389
- ¹³C-breath test, 109
- ¹³C-urea, 1001
- Cadeddu, F. *see* Brisinda, G.
- Cadeddu, F. *see* Brisinda, G.
- calprotectin, 615
- Cameron, A.J. *see* Nandurkar, S.
- Camarota, G. *see* Nista, E.C.
- Campbell, M.S. & Reddy, K.R. Review article: the evolving role of liver biopsy, 249
- cancer screening, 381
- cancer, 445
- Candelli, M. *see* Nista, E.C.
- candidiasis, 475
- Capristo, E. *see* Addolorato, G.
- capsule endoscopy, 1083
- Card, T.R. *see* West, J.
- Card, T.R., West, J. & Holmes, G.K.T. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study, 769
- Cardenas, A., Kelleher, T. & Chopra, S. Review article: hepatic hydrothorax, 271
- cardiac chest pain, 909
- cardiovascular, 51
- Carnicer, F. *see* Zapater, P.
- Carreño, V. *see* Barril, G.
- Carrera, E. *see* Lopez-Sanroman, A.
- Cascavilla, L. *see* Pilotto, A.
- case control, 497
- Caspary, W.F. *see* Kerber, A.
- Casswall, T.H. *see* Tindberg, Y.
- Castell, D.O. *see* Katz, P.O.
- Cazzato, I.A. *see* Nista, E.C.
- celiac disease, 73, 231
- cerebral hypoperfusion, 821
- Chan, A.O.O. *see* Gu, Q.
- Chan, C.K. *see* Wong, W.M.
- Chan, F.K.L. *see* Sung, J.J.Y.
- Chan, F.K.-L. *see* Wong, V.W.-S.
- Chan, H.L.-Y. *see* Wong, V.W.-S.
- Chan, K.-F. *see* Wong, V.W.-S.
- Chan, L.S. *see* Sung, J.J.Y.
- Chand, N., Johnson, D.A., Tabangin, M. & Ware, J.C. Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study, 969
- Chang, L. *see* Labus, J.S.
- change in diagnoses, 803
- Chapman, R. *see* Tsai, H.H.
- Chen, A., Li, C.-N., Hsu, P.-L., Lai, K.-H., Tseng, H.-H., Hsu, P.-N., Lo, G.-H., Lo, C.-C., Lin, C.-K., Hwang, I.-R., Yamaoka, Y. & Chen, H.-C. Risks of interleukin-1 genetic polymorphisms and *Helicobacter pylori* infection in the development of gastric cancer, 203
- Chen, H.-C. *see* Chen, A.
- Chen, J.D.Z. *see* Ouyang, H.
- Chen, Y. *see* Katz, P.O.
- chest pain, 909
- Cheung, H.K.-L. *see* Gu, Q.
- Chiba, N. *see* Fallone, C.A.
- children, 167, 295
- Childs, S. *see* Raghunath, A.S.
- Ching, J.Y.L. *see* Sung, J.J.Y.
- Chinuki, D. *see* Amano, Y.
- Chiu, Y.-L. *see* Kovacs, T.O.G.
- choice, 989
- Chopra, S. *see* Cardenas, A.
- chronic hepatitis C, 1189
- ciclosporin, 143
- Ciociola, A.A. *see* Rodriguez-Stanley, S.
- cirrhosis, 29, 271
- Claessens, G. *see* Pierik, M.
- clarithromycin, 99
- Clark, W. *see* Marshall, J.K.
- coagulation, 289
- coeliac disease, 769, 777, 821
- cohort study, 577, 751
- Colin, P. *see* Konstan, M.W.
- colitis, 697
- collagenous colitis, 745
- Collette, J. *see* Franchimont, N.

- Collins, S.M. *for the WEL Investigators* see Marshall, J.K.
 Colombel, J.F. see Annese, V.
 colon, 983
 colonic diseases functional, 1195
 colonoscopy, 381, 507
 colorectal cancer, 507, 1115
 combination interferon and ribavirin therapy, 629
 comorbidity, 1195
 conclusions, 567
 Consolazio, A., Borgia, M.C., Ferro, D., Iacopini, F., Paoluzi, O.A., Crispino, P., Nardi, F., Rivera, M. & Paoluzi, P. Increased thrombin generation and circulating levels of tumour necrosis factor- α in patients with chronic *Helicobacter pylori*-positive gastritis, 289
 constipation, 355
 Contos, M.J. see Sterling, R.K.
 controlled release, 347
 coronary heart disease, 289
 Corrigan, B.W. see Koch, K.M.
 Corritore, G. see Annese, V.
 cost effectiveness, 593
 cost, 657
 cost-benefit analysis, 939
 cost-benefit, 321
 cost-effectiveness, 195
 COX-2 expression, 793
 COX-2 inhibitors, 1035
 COX-2 selective inhibitors, 321, 527
 Cremonini, F. see Nista, E.C.
 Crispino, P. see Consolazio, A.
 Crohn's disease, 151, 167, 483, 585, 607, 843, 951, 959, 1019, 1143
 current depression, 777
 cyclooxygenase, 675
 cyclooxygenase-2 inhibitor, 51
 CYPIA2, 223
 cystic fibrosis, 813
 D'Angelo, C. see Leggio, L.
 Dahab, S.T. see Khuroo, M.S.
 Dalhoff, K. see Schmidt, L.E.
 Danelli, P.G. see Parente, F.
 Daniel, J. see Sacian, K.
 Davies, S. see Afzal, N.A.
 Davila, J.A. see Rabeneck, L.
 Davis, K.J., Kumar, D. & Poloniecki, J. Adjuvant biofeedback following anal sphincter repair: a randomized study, 539
 daytime/nighttime heartburn, 1105
 De Herdt, D. see Bytzer, P.
 De Lorenzi, G. see Addolorato, G.
 De Maeght, S. see Delwaide, J.
 De Micheli, E. see Frazzoni, M.
 De Vos, M. see Franchimont, N.
 decision analysis, 939
 deficiency, 1029
 Degl'Innocenti, A. see Fallone, C.A.
 Delchier, J.C. see Bruley des Varannes, S.
 Delvaux, M., Beck, A., Jacob, J., Bouzamondo, H., Weber, F.T. & Frexinos, J. Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome, 237
 Delwaide, J., Bourgeois, N., Gérard, C., De Maeght, S., Mokaddem, F., Wain, E., Bastens, B., Fevery, J., Géhénot, M., Le Moine, O., Martinet, J.P., Robaeys, G., Servais, B., Van Gossum, M., Van Vlierberghe, H. & The Belgian Association for the Study of the Liver (BASL) Treatment of acute hepatitis C with interferon α -2b: early initiation of treatment is the most effective predictive factor of sustained viral response, 15
 Dent, J. see Ruigómez, A.
 depression, 917
 Derkx, B. see Afzal, N.A.
 DeVault, K.R. see Wolfsen, H.C.
 DeWitt, J.E. see Feyen, B.
 Di Giuda, D. see Leggio, L.
 Di Mario, F. see Pilotto, A.
 diabetic gastroparesis, 333
 diagnosis, 469, 1001, 1063
 dialysis, 1053
 dialyzer pore size, 37
 Díaz-Rubio, M. see Rey, E.
 Dickason, J. see Fischbach, L.A.
 Diehl, A.M. see Nair, S.
 diet, 231, 497
 Dikici, B. see Özgenc, F.
 Dinasquet, M. see Siproudhis, L.
 disease outcome, 483
 distal ulcerative colitis, 783
 Dixit, V. see Fabrizi, F.
 Dolwani, S., Metzner, M., Wassell, J.J., Yong, A. & Hawthorne, A.B. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology, 615
 Domènech, E., Hinojosa, J., Esteve-Comas, M., Gomollón, F., Herrera, J.M., Bastida, G., Obrador, A., Ruiz, R., Saro, C., Gassull, M.A. & Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) Granulocyteapheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study, 1347
 Donoghue, J. see Blacka, J.
 dosage forms, 883
 dose escalation, 65
 double-blind, 295
 Drapers, J.A.G. see West, R.L.
 Dressman, J.B. see Bott, C.
 Drossman, D.A. see Whitehead, W.E.
 Dubois, D. see Bytzer, P.
 DuBois, S. & Kowdley, K.V. Review article: targeted screening for hereditary haemochromatosis in high-risk groups, 1
 Duggan, C. see Konstan, M.W.
 Duggan, S. see Tsai, H.H.
 Dulai, G. see Fabrizi, F.
 van Dullemen, H.M. see Weersma, R.K.
 duodenal disorder, 413
 duodenal ulcer, 733
 duodenum, 517
 dyspepsia classification, 1171
 dyspepsia, 99, 469, 1171

- Easley, K. *see* Stevens, T.
echinocandin, 475
efficacy, 783, 1071
 Eghtesad, B. *see* Neff, G.W.
 Ehrsam, E. *see* Hawkey, C.J.
 Eigen, H. *see* Konstan, M.W.
 Eisen, G.M. *see* Eliakim, R.
 Eisen, G.M. *see* Goldstein, J.L.
elderly, 1115
 El-Dika, S. *see* Fallone, C.A.
electroacupuncture, 831
 Eliakim, R., Yassin, K., Shlomi, I., Suissa, A. & Eisen, G.M. A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule, 1083
 El-Serag, H. *see* Kulkarni, K.
 El-Serag, H.B. *see* Rabeneck, L.
 Emmanuel, A.V. *see* Rayner, C.K.
endoscopic therapy, 195
endoscopy surveillance, 1125
endoscopy, 989, 1083
 ENRD, 657
enteral nutrition, 167
Enzyme-Linked Immunosorbent Assay (ELISA), 585
epidemiology, 73, 373, 483, 551, 697, 719, 751, 769
eradication, 733
 Ermani, M. *see* Briani, C.
erosive oesophagitis, 883
erythropoietin, 437
 Eslick, G.D. & Talley, N.J. Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities, 909
esomeprazole, 399, 413, 657, 969, 1099
 Esteban, A. *see* Zapater, P.
 Esteve-Comas, M. *see* Domènech, E.
ethanol metabolism, 109
ethnic differences, 705
Eudragit®, 347
EuroQol, 311
 Evans, B.K. *see* Ingram, J.R.
exercise, 497
extrahepatic manifestations, 129
 Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis, 1271
 Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease, 1053
 Fabrizi, F. & Martin, P. Author's reply: 123
 Facklam, D. *see* Pettengell, K.
 Fadda, M. *see* Gaia, S.
 Fallone, C.A. *see* Barkun, A.N.
 Fallone, C.A., Barkun, A.N., Mayrand, S., Wakil, G., Friedman, G., Szilagyi, A., Wheeler, C. & Ross, D. There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with *Helicobacter pylori*, 761
 Fallone, C.A., Guyatt, G.H., Armstrong, D., Wiklund, I., Degl'Innocenti, A., Heels-Ansdell, D., Barkun, A.N., Chiba, N., van Zanten, S.J.O., El-Dika, S., Austin, P., Tanser, L. & Schünemann, H.J. Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? 1161
famotidine, 559
 Färkkilä, M.A. *see* Hillilä, M.T.
 Farkouh, M. *see* Hawkey, C.J.
 Farr Jr, G.H. *see* Nair, S.
 Farup, P.G. *see* Vandvik, P.O.
fatty liver, 45
fecal calprotectin, 813
fecal incontinence, 355, 539, 667
feeling thermometer, 1161
 Feld, A.D. *see* Whitehead, W.E.
 Fell, J.M. *see* Afzal, N.A.
 Felt-Bersma, R.J.F. *see* West, R.L.
 Fendrick, A.M. *see* Vijan, S.
 Fenn, R.M.F. *see* Boulton-Jones, J.R.
 Fennerty, M.B. *see* Lee, T.J.
 Ferlitsch, A. *see* Homoncik, M.
 Fernández-Esparrach, G. *see* Mata, A.
 Ferro, D. *see* Consolazio, A.
 Fett, S. *see* Nandurkar, S.
 Feu, F. *see* Mata, A.
 Fevery, J. *see* Delwaide, J.
 Feyen, B., Wall, G.C., Finnerty, E.P., DeWitt, J.E. & Reyes, R.S. Meta-analysis: budesonide treatment for collagenous colitis, 745
 Feyerabend, C. *see* Ingram, J.R.
 Fiasse, R. *see* Franchimont, N.
 Fincke, C. *see* Harrison, S.A.
 Finnerty, E.P. *see* Feyen, B.
 Fischbach, L.A., van Zanten, S.V. & Dickason, J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies, 1071
fistulas, 585
fluoxetine, 689
focal liver lesion, 249
 Forbes, A. *see* Bardhan, K.D.
 Formicola, V. *see* Bruzzese, E.
 Forrest, K., Symmons, D. & Foster, P. Systematic review: Is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? 1035
 Foster, G.R. Review article: Pegylated interferons: chemical and clinical differences, 825
 Foster, P. *see* Forrest, K.
fracture, 551
 Fraga, P. *see* Richter, J.E.
 Fraga, P.D. *see* Bochenek, W.J.
 Frances, R. *see* Zapater, P.
 Franceschi, F. *see* Nista, E.C.
 Franceschi, M. *see* Pilotto, A.
 Franchimont, D. *see* Franchimont, N.
 Franchimont, N., Putzeys, V., Collette, J., Vermeire, S., Rutgeerts, P., De Vos, M., Van Gossum, A., Franchimont, D., Fiasse, R., Pelckmans, P., Malaise, M., Belaiche, J. & Louis, E. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease, 607
 Franco, J. *see* Saecian, K.

- Fransen, G.A.J., Janssen, M.J.R., Muris, J.W.M., Laheij, R.J.F. & Jansen, J.B.M.J. Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy, 1045
- Frazzoni, M., De Micheli, E., Zentilin, P. & Savarino, V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn, 81
- Freston, J.W., Kukulka, M.J., Lloyd, E. & Lee, C. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube, 407
- Frexinos, J. *see* Delvaux, M.
- Fried, M. *see* Lesbros-Pantoflickova, D.
- Friedman, G. *see* Fallone, C.A.
- Fueyo, A. *see* Rey, E.
- Fujisawa, T., Adachi, K., Komazawa, Y., Mihara, T., Azumi, T., Katsube, T., Furuta, K., Kazumori, H. & Kinoshita, Y. *Helicobacter pylori* infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists, 559
- Fulcher, A.S. *see* Sterling, R.K.
- functional dyspepsia, 365, 423
- functional gastrointestinal disorders, 831
- functional heartburn, 81, 975
- Fung, J. *see* Neff, G.W.
- Furuta, K. *see* Fujisawa, T.
- Gaffney, D. *see* Winter, J.
- Gaia, S., Marzano, A., Smedile, A., Barbon, V., Abate, M.L., Olivero, A., Lagget, M., Paganin, S., Fadda, M., Niro, G. & Rizzetto, M. Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B, 281
- Gallus, S. *see* Parente, F.
- game therapy, 381
- ganglioside, 231
- Gao, Q., van Hozegand, R.A., Lamers, C.B.H.W. & Verspaget, H.W. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease, 585
- García Rodríguez, L.A. *see* Ruigómez, A.
- García-Buey, L. *see* Medina, J.
- García-Plaza, A. *see* Lopez-Sanroman, A.
- Gardner, J.D., Sloan, S., Robinson, M. & Miner Jr, P.B. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor, 1381
- Gardner, J.D., Sloan, S., Robinson, M. & Miner, P.B. Oesophageal pH has a power-law distribution in control and gastro-oesophageal reflux disease subjects, 1373
- Garg, A.X. *see* Marshall, J.K.
- Gasbarrini, A. *see* Nista, E.C.
- Gasbarrini, G. *see* Addolorato, G.
- Gasbarrini, G. *see* Leggio, L.
- Gasbarrini, G. *see* Nista, E.C.
- Gassull, M.A. for the Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) *see* Domènech, E.
- gastoprotection, 1091
- gastric alcalinization, 683
- gastric cancer, 261, 1045
- gastric disorder, 413
- gastric emptying, 333
- gastric myoelectrical activity, 831
- gastric pH, 683
- gastritis, 109
- gastrointestinal bleeding, 195, 321
- gastrointestinal endoscopy, 381
- gastrointestinal hemorrhage, 381
- gastrointestinal motility, 831
- gastrointestinal oncology, 983
- gastrointestinal symptom rating scale (GSRS), 761, 891
- gastrointestinal symptoms, 311
- gastrointestinal transit, 347
- gastrointestinal, 51
- gastrointestinal endoscopy, 939
- gastro-oesophageal reflux disease, 81, 389, 399, 451, 567, 637, 705, 719, 761, 803, 891, 909, 969, 1083, 1105, 1153, 1161
- gastro-oesophageal reflux, 733, 751
- gastroscopy, 989
- Gatta, L., Perna, F., Ricci, C., Osborn, J.F., Tampieri, A., Bernabucci, V., Miglioli, M. & Vaira, D. A rapid immunochromatographic assay for *Helicobacter pylori* in stool before and after treatment, 469
- Gatz, G. *see* Bardhan, K.D.
- Gaudiello, G. *see* Bruzzese, E.
- Géhénot, M. *see* Delwaide, J.
- Geldof, H. *see* de Wit, N.J.
- general practice, 751, 1195
- geographical differences, 705
- Gérard, C. *see* Delwaide, J.
- Gerson, L.B., Boparai, V., Ullah, N. & Triadafilopoulos, G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors, 637
- Getachew, Y., Browning, J.D., Prebis, M., Rogers, T. & Brown, G.R. Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation, 629
- Gharib, H. *see* Bruley des Varannes, S.
- Ghosh, S. *see* Winter, T.A.
- Giles, N. *see* Russo, A.
- Ginés, A. *see* Mata, A.
- Gisbert, J.P. & Pajares, J.M. Review article: ¹³C-urea breath test in the diagnosis of *Helicobacter pylori* infection, 1001
- Gitton, X. *see* Hawkey, C.J.
- gluten, 231
- gluten-free diet, 777, 821
- Goldman, C. *see* Salgueiro, J.
- Goldstein, J.L., Eisen, G.M., Agrawal, N., Stenson, W.F., Kent, J.D. & Verburg, K.M. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib, 527
- Gomollón, F. *see* Domènech, E.
- Goodgame, R. *see* Kulkarni, K.
- Gorard, D.A. *see* Olithselvan, A.
- Gordon, C., Kang, J.Y., Neild, P.J. & Maxwell, J.D. Review article: the role of the hiatus hernia in gastro-oesophageal reflux disease, 719
- graded method, 431

- Graffner, H. *see* Ruigómez, A.
 Granström, M. *see* Tindberg, Y.
granulocyte and monocyte adsorptive apheresis, 783
granulomatosis diseases, 1019
 Greco, S. *see* Parente, F.
 Green, J. *see* Armstrong, D.
 Greenwood, R. *see* Tobias, J.H.
 Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) *see* Domènech, E.
 Gu, Q., Xia, H.H.-X., Wang, W.H., Wang, J.D., Wong, W.M., Chan, A.O.O., Yuen, M.F., Lam, S.K., Cheung, H.K.-L., Liu, X.G. & Wong, B.C.-Y. Effect of cyclo-oxygenase inhibitors on *Helicobacter pylori* susceptibility to metronidazole and clarithromycin, 675
 Guarino, A. *see* Bruzzese, E.
 Guariso, G. *see* Briani, C.
 Guda, N., Partington, S. & Vakil, N. Symptomatic gastro-oesophageal reflux, arousals and sleep quality in patients undergoing polysomnography for possible obstructive sleep apnoea, 1153
 Guyatt, G.H. *see* Fallone, C.A.
- van Haastert, M. *see* Weersma, R.K.
 Hallas, J. *see* Lassen, A.
 Hallerbäck, B. *see* Wilder-Smith, C.H.
 Hansen, B.E. *see* West, R.L.
 Harker, J. *see* Ramirez, F.C.
 Harrison, S.A., Fincke, C., Helinski, D., Torgerson, S. & Hayashi, P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients, 623
 Hart, A.L. *see* Rayner, C.K.
 Hasunuma, O. *see* Kato, K.
 Hawkey, C.J., Farkouh, M., Gitton, X., Ehrsam, E., Huels, J. & Richardson, P. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics, 51
 Hawthorne, A.B. *see* Dolwani, S.
 Hayashi, P. *see* Harrison, S.A.
 Hayes, P.C. *see* Younger, H.M.
 Hayward, C.M.M. *see* Rayner, C.K.
 Hayward, R.A. *see* Vijan, S.
 Hazelhoff, B. *see* de Wit, N.J.
 HBV, 281
health care seeking, 909
health economics, 939
health related quality of life, 311, 1161
health service research, 381, 939
healthy volunteers, 689
heartburn, 81, 181, 389, 413, 451, 705, 719
 Heels-Ansdell, D. *see* Fallone, C.A.
Helicobacter pylori treatment, 99
Helicobacter pylori, 109, 117, 261, 289, 295, 381, 451, 469, 559, 675, 733, 761, 1001, 1029, 1071, 1181
 Helinski, D. *see* Harrison, S.A.
 Hemminger, L.L. *see* Wolfson, H.C.
hemochromatosis, 1
hemodialysis, 37
hemolysis, 1189
 Hendrickse, M.T. *see* Tsibouris, P.
hepatic hydrothorax, 271
hepatitis B immunoglobulin, 993
hepatitis B virus, 993, 1053
hepatitis B, 249
hepatitis C virus infection, 129
hepatitis C virus, 931
hepatitis C, 249, 445, 629, 917
hepatocellular carcinoma, 445, 983
 Herba, K. *see* Barkun, A.N.
herbals, 1205
 Herrera, J.M. *see* Domènech, E.
 Herrlinger, K. *see* Kerber, A.
 Heuschkel, R. *see* Afzal, N.A.
HFE gene, 1
hiatus hernia, 705, 719
 Higgins, P.D.R. *see* Laine, L.
 Hillilä, M.T. & Färkkilä, M.A. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population, 339
 Hinojosa, J. *see* Domènech, E.
 Ho, S. *see* Saeian, K.
 Ho, Y.P. *see* Sung, J.J.Y.
 Hodgson, T. *see* Leão, J.C.
 Hofer, T.P. *see* Vijan, S.
 Hogan, S.P. & Rothenberg, M.E. Review article: the eosinophil as a therapeutic target in gastrointestinal disease, 1231
 van Hogeand, R.A. *see* Gao, Q.
 Holland, J.F. *see* Ramirez, F.C.
 Holmes, G.K.T. *see* Card, T.R.
 Homan van der Heide, J.J. *see* Weersma, R.K.
 Homoncik, M., Jilma-Stohlawetz, P., Schmid, M., Ferlitsch, A. & Peck-Radosavljevic, M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study, 437
 Horga, J.F. *see* Zapater, P.
hormones, 237
 Horowitz, M. *see* Russo, A.
 Howden, C.W. *see* Lee, T.J.
 Hsu, P.-I. *see* Chen, A.
 Hsu, P.-N. *see* Chen, A.
 Hu, W.H.C. *see* Wong, W.M.
 Huang, J.Q. *see* Wong, W.M.
 Hubbard, R. *see* West, J.
 Huels, J. *see* Hawkey, C.J.
 Hui, A.Y. *see* Wong, V.W.-S.
 Hui, W.M. *see* Wong, W.M.
human immunodeficiency virus, 993
 Hungin, A.P.S. *see* Raghunath, A.S.
 Hwang, I.-R. *see* Chen, A.
hypercholesterolaemia, 73
hypertension, 73
- Iacopini, F. *see* Consolazio, A.
 IBS-C, 213
ibuprofen, 51
icterus, 15
 Ihlebæk, C. *see* Vandvik, P.O.
 Imaoka, A. *see* Kato, K.
immigration, 445

- immune complex deposition, 129
immunology and microbiology, 303
immunomodulators, 601
Inadomi, J. *see* Vijan, S.
index terms, 883
indirect costs, 459
inflammation, 615
inflammatory bowel disease, 65, 161, 303, 615, 951, 1035, 1143
inflammatory disorders, 303, 593, 601, 607, 851, 859
infliximab, 151, 303, 585, 607, 851
Ingram, J.R., Routledge, P., Rhodes, J., Marshall, R.W., Buss, D.C., Evans, B.K., Feyerabend, C. & Thomas, G.A.O. Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine, 859
Innes, A. *see* Winter, T.A.
insulin resistance, 23
intra-gastric pH, 399
interferon, 15, 917, 931, 1189
interferon- α , 129
international validation, 891
intestinal disorders, 237, 303, 339, 593, 601, 607, 851.
intestinal inflammation, 813
intra-gastric acidity, 899
intraluminal fungal colonization, 875
intravenous, 883, 1099
iron, 1
irritable bowel syndrome, 89, 213, 339, 459, 615, 1195, 1205
Isaacs, P.E.T. *see* Tsibouris, P.
ischaemic, 697
Ishihara, S. *see* Amano, Y.
Ishii, H. *see* Suzuki, M.
Ishii, Y. *see* Kato, K.
Ishimura, N. *see* Amano, Y.
Iwasaki, A. *see* Kato, K.

Jacob, J. *see* Delvaux, M.
Jahnsen, J. *see* Winter, T.A.
James, C.D. *see* Koch, K.M.
Jansen, J.B.M.J. *see* Bovenschen, H.J.
Jansen, J.B.M.J. *see* Fransen, G.A.J.
Jansen, P.L.M. *see* Weersma, R.K.
Janssen, M.J.R. *see* Fransen, G.A.J.
Jilma-Stohlawetz, P. *see* Homoncik, M.
Johansson, S. *see* Ruigómez, A.
Johnson, D.A. *see* Chand, N.
Jones, K.L. *see* Russo, A.
Joossens, S. *see* Pierik, M.
Junghard, O. *see* Armstrong, D.

Kamm, M.A. *see* Rayner, C.K.
Kang, J.Y. *see* Gordon, C.
Kang, J.Y. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease, 705
Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A. & Arakawa, Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis, 1133
Katsube, T. *see* Fujisawa, T.
Katz, P.O., Castell, D.O., Chen, Y., Andersson, T. & Sostek, M.B. Intra-gastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study, 399
Kazumori, H. *see* Fujisawa, T.
KC11458, 333
Kelleher, T. *see* Cardenas, A.
Kelty, C.J., Ackroyd, R., Brown, N.J., Stephenson, T.J., Stoddard, C.J. & Reed, M.W.R. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation, 1289
Kennedy, W. *see* Barkun, A.N.
Kent, J.D. *see* Goldstein, J.L.
Kerber, A., Trojan, J., Herrlinger, K., Zgouras, D., Caspary, W.F. & Braden, B. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study, 983
Kersey, K.E. *see* Koch, K.M.
Khuroo, M.S. *see* Khuroo, M.S.
Khuroo, M.S., Khuroo, M.S. & Dahab, S.T. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4, 931
Kinoshita, Y. *see* Amano, Y.
Kinoshita, Y. *see* Fujisawa, T.
Kitagawa, T. *see* Yamamoto, T.
Kluyts, T. *see* Pettengell, K.
Knox, J.F. *see* Saecian, K.
Koch, K.M., Corrigan, B.W., Manzo, J., James, C.D., Scott, R.J., Stead, A.G. & Kersey, K.E. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors, 223
Komazawa, Y. *see* Fujisawa, T.
Konstan, M.W., Stern, R.C., Trout, J.R., Sherman, J.M., Eigen, H., Wagener, J.S., Duggan, C., Wohl, M.E.B. & Colin, P. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy, 1365
Kovacs, T.O.G., Lee, C.Q., Chiu, Y.-L., Pilmer, B.L. & Metz, D.C. Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis, 883
Kowdley, K.V. *see* DuBois, S.
Krause, G. *see* Russo, A.
Kugelman, M. *see* Attwell, A.
Kuipers, E.J. *see* West, R.L.
Kulkulka, M.J. *see* Freston, J.W.
Kulasingham, S.L. *see* Orlando, L.A.
Kulkarni, K., Barcak, E., El-Serag, H. & Goodgame, R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States, 445
Kumar, D. *see* Davis, K.J.
Kurihara, R. *see* Kato, K.
Kushiyama, Y. *see* Amano, Y.

Labus, J.S., Bolus, R., Chang, L., Wiklund, I., Naesdal, J., Mayer, E.A. & Naliboff, B.D. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale, 89

- lafutidine*, 559
 Lagget, M. *see* Gaia, S.
 Laheij, R.J.F. *see* Bovenschen, H.J.
 Laheij, R.J.F. *see* Fransen, G.A.J.
 Lai, K.C. *see* Wong, W.M.
 Lai, K.-H. *see* Chen, A.
 Laine, L. *see* Rubenstein, J.H.
 Laine, L. & Higgins, P.D.R. Author's reply, 697
 Lam, C.L.K. *see* Wong, W.M.
 Lam, K.F. *see* Wong, W.M.
 Lam, S.K. *see* Gu, Q.
 Lam, S.K. *see* Wong, W.M.
 Lamers, C.B.H.W. *see* Gao, Q.
lamivudine, 993
 Lanas, A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract, 321
 Langguth, P. *see* Bott, C.
lansoprazole, 407, 657, 883
 Lanza, F. *see* Vakil, N.
 Lao, L. *see* Sung, J.J.Y.
 Lashner, B. *see* Stevens, T.
 Lassen, A., Hallas, J. & Schaffalitzky de Muckadell, O.B. Use of anti-secretory medication: a population-based cohort study, 577
 Lasso de la Vega, M.C. *see* Zapater, P.
 Latiano, A. *see* Annese, V.
 Lau, W. *see* Pettengell, K.
 Lauritsen, K. *see* Armstrong, D.
 Laverigne-Slove, A. *see* de Saussure, P.
 Le Moine, O. *see* Delwaide, J.
 Leandro, G. *see* Pilotto, A.
 Leão, J.C., Hodgson, T., Scully, C. & Porter, S. Review article: orofacial granulomatosis, 1019
 Lee, C. *see* Freston, J.W.
 Lee, C.Q. *see* Kovacs, T.O.G.
 Lee, T.J., Fennerty, M.B. & Howden, C.W. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? 1241
 Leggio, L. *see* Addolorato, G.
 Leggio, L., Abenavoli, L., D'Angelo, C., Di Giuda, D., Gasbarrini, G. & Addolorato, G. Gluten-related cerebral hypoperfusion and neurologic disorders in coeliac patients, 821
 Leonardi, N. *see* Salgueiro, J.
 Lesbros-Pantoflickova, D., Michetti, P., Fried, M., Beglinger, C. & Blum, A.L. Meta-analysis: the treatment of irritable bowel syndrome, 1253
 Leung, F.W. *see* Ramirez, F.C.
 Leung, W.K. *see* Sung, J.J.Y.
 Levine, A., Shevah, O., Shabat-Schayek, V., Aeed, H., Boaz, M., Moss, S.F., Niv, Y., Avni, Y. & Shirin, H. Masking of ^{13}C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole, 117
 Levy, R.L. *see* Whitehead, W.E.
 Li, C.-N. *see* Chen, A.
 Liang, S.M. *see* Sung, J.J.Y.
 Liew, C.-T. *see* Wong, V.W.-S.
 Lin, C.-K. *see* Chen, A.
 Lind, T. *see* Armstrong, D.
 Liu, X.G. *see* Gu, Q.
liver biopsy, 45, 249
liver descriptors, 281, 623, 1189
liver failure, 173
liver function test, 45
liver transplantation, 867, 993
liver, 445
 Llach, J. *see* Mata, A.
 Lloyd, E. *see* Freston, J.W.
 Lo, C.-C. *see* Chen, A.
 Lo, G.-H. *see* Chen, A.
 Locke III, G.R. *see* Bharucha, A.E.
 Locke III, G.R. *see* Nandurkar, S.
 Logan, R.F.A. *see* Boulton-Jones, J.R.
 Logan, R.F.A. *see* West, J.
 Lombardi, G. *see* Annese, V.
 Longo, M.G. *see* Pilotto, A.
 Lopez-Sanroman, A., Bermejo, F., Carrera, E. & Garcia-Plaza, A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis, 161
 Louis, E. *see* Franchimont, N.
lower oesophageal sphincter, 719
 Ludkowski, M. *see* Attwell, A.
 Luketic, V.A. *see* Sterling, R.K.
lumiracoxib, 51
lymphoma, 769
 Mabisombi, A. *see* Brisinda, G.
 McIntyre, A.S. *see* Olithselvan, A.
 Mack, M. *see* Richter, J.E.
 Mack, M.E. *see* Bochenek, W.J.
 McKee, D. *see* Saecian, K.
 McKeith, D. *see* Tsai, H.H.
 Madalinski, M. The treatment algorithm instead of the unknown optimal dose of botulinum toxin for chronic anal fissure, 123
 Madsen, L.G., Wallin, L. & Bytzer, P. Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial – is gastro-oesophageal reflux important? 423
 Madsen, L.G. & Bytzer, P. Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design, 365
maintenance therapy, 181, 567
maintenance, 213, 657
 Malaise, M. *see* Franchimont, N.
 Malekzadeh, R. *see* Mikaeli, J.
 Malferteiner, P. *see* Nardone, G.
malignancy, 769, 1045
 Manzo, J. *see* Koch, K.M.
 Maria, G. *see* Brisinda, G.
 Marsden, C.L. *see* Bardhan, K.D.
 Marshall, J.K., Thabane, M., Garg, A.X., Clark, W., Meddings, J., Collins, S.M. & for the wel Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, 1317
 Marshall, R.W. *see* Ingram, J.R.
 Martin, P. *see* Fabrizi, F.
 Martincich, I. *see* Blacka, J.
 Martinet, J.P. *see* Delwaide, J.

- Martinez Sarraague, M. *see* Salgueiro, J.
 Maruyama, K. *see* Suzuki, M.
 Marzano, A. *see* Gaia, S.
 Mason, T. *see* Bardhan, K.D.
 Mata, A., Bordas, J.M., Feu, F., Ginés, A., Pellisé, M., Fernández-Esparrach, G., Balaguer, F., Piqué, J.M. & Llach, J. Wireless capsule endoscopy in patients with obscure gastrointestinal bleeding: a comparative study with push enteroscopy, 189
 Matchar, D.B. *see* Orlando, L.A.
 Matsumoto, K. *see* Yamamoto, T.
 Matuchansky, C. *see* de Saussure, P.
 Maxwell, J.D. *see* Gordon, C.
 Mayer, E.A. *see* Labus, J.S.
 Mayrand, S. *see* Fallone, C.A.
 Mazeron, M.-C. *see* de Saussure, P.
 Meddings, J. *see* Marshall, J.K.
medical decision analysis, 381
medical procedure, 15
medical ritual, 939
 Medina, J., García-Buey, L. & Moreno-Otero, R. Review article: hepatitis C virus-related extra-hepatic disease — aetiopathogenesis and management, 129
 Meineche-Schmidt, V. Classification of dyspepsia and response to treatment with proton-pump inhibitors, 1171
 Melkersson Rosenthal syndrome, 1019
 Melzer, J., Rösch, W., Reichling, J., Brignoli, R. & Saller, R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast), 1279
 Meredith, G. *see* Blacka, J.
meta-analysis, 745, 1045, 1053, 1071
metabolic syndrome, 45
metabolism, 223
metabolites, 601
metastasis, 983
metformin, 23
methotrexate hepatotoxicity, 249
methotrexate, 151
 Metz, D.C. *see* Bochenek, W.J.
 Metz, D.C. *see* Kovacs, T.O.G.
 Metzner, M. *see* Dolwani, S.
micafungin, 475
 Michetti, P. *see* Lesbros-Pantoflickova, D.
micronutrient, 1029
 Miglioli, M. *see* Gatta, L.
 Mihara, T. *see* Fujisawa, T.
 Mikaeli, J., Bishehsari, F., Montazeri, G., Yaghoobi, M. & Malekzadeh, R. Pneumatic balloon dilatation in achalasia: a prospective comparison of safety and efficacy with different balloon diameters, 431
 Mills, A.S. *see* Sterling, R.K.
 Mills, P.R. *see* Winter, J.
 Miner Jr, P.B. *see* Gardner, J.D.
 Miner Jr, P.B. *see* Rodriguez-Stanley, S.
 Miner, P.B. *see* Gardner, J.D.
minerals, 1029
 Mitten-Lewis, S. *see* Blacka, J.
 Miyake, T. *see* Amano, Y.
 Miyaoka, Y. *see* Amano, Y.
 Mizuno, S. *see* Kato, K.
 Mokaddem, F. *see* Delwaide, J.
molecular alterations, 261
 Molteni, M. *see* Parente, F.
 Mönnikes, H. *see* Bardhan, K.D.
 Montazeri, G. *see* Mikaeli, J.
 Moreno-Otero, R. *see* Medina, J.
 Morris, P. *see* Blacka, J.
 Moss, S.F. *see* Levine, A.
 Mössner, J. *see* Armstrong, D.
motilin, 333
motility and nerve-gut interactions, 237, 339, 689
 Moum, B. *see* Armstrong, D.
mucin-phenotype, 793
mucosal healing, 167
mucus secretion, 517
 Mukumoto, M. *see* Yamamoto, T.
 Murch, S. *see* Afzal, N.A.
 Muris, J.W.M. *see* Fransen, G.A.J.
mycophenolate mofetil, 943
 Mynhardt, J. *see* Pettengell, K.
myocardial infarction, 73
 Naesdal, J. *see* Labus, J.S.
nagogastric tube, 407
 Nair, S., Diehl, A.M., Wiseman, M., Farr Jr, G.H. & Perrillo, R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial, 23
 Naliboff, B.D. *see* Labus, J.S.
 Nandurkar, S., Locke III, G.R., Fett, S., Zinsmeister, A.R., Cameron, A.J. & Talley, N.J. Relationship between body mass index, diet, exercise and gastro-oesophageal reflux symptoms in a community, 497
 Napolitano, G. *see* Annesse, V.
naproxen, 51
 Nardi, F. *see* Consolazio, A.
 Nardone, G., Rocco, A. & Malfertheiner, P. Review article: *Helicobacter pylori* and molecular events in precancerous gastric lesions, 261
 NASH, 623
 Nash, R. *see* Attwell, A.
 Naumann, M. *see* Schröder, O.
nausea and vomiting, 831
needle-stick, 15
 Neff, G.W., Sherman, K.E., Egtesad, B. & Fung, J. Review article: current status of liver transplantation in HIV-infected patients, 993
 Neild, P.J. *see* Gordon, C.
neurologic disorders, 821
neuropathy, 231
neutropenia, 917
 NG tube, 407
 Niazi, S. *see* Ozturk, R.
nicotine enema, 859
 Niro, G. *see* Gaia, S.
 Niro, V. *see* Pilotto, A.
 Nishimura, N. *see* Yamamoto, T.
 Nista, E.C., Candelli, M., Cremonini, F., Cazzato, L.A., Zocco, M.A., Franceschi, F., Cammarota, G., Gasbarrini, G. & Gasbarrini, A. *Bacillus clausii* therapy to reduce side-effects of anti-*Helicobacter*

- pylori* treatment: randomized, double-blind, placebo controlled trial, 1181
- nitric oxide, 813
- Niv, Y. *see* Levine, A.
- non alcoholic steatohepatitis, 23
- non-alcoholic fatty liver disease, 249
- non-cardiac chest pain, 909
- non-erosive gastro-oesophageal reflux disease, 181
- non-erosive reflux disease, 81, 389
- non-steroidal anti-inflammatory agents, 373
- non-steroidal anti-inflammatory drugs, 321, 517, 577, 645, 793, 1035, 1091
- obesity, 623
- Obrador, A. *see* Domènech, E.
- obscure gastrointestinal bleeding, 189
- observer variation, 1205
- O'Donovan, D.G. *see* Russo, A.
- oesophageal adenocarcinoma, 645
- oesophageal and gastric ambulatory pH monitoring, 637
- oesophageal cancer, 1045
- oesophageal capsule, 1083
- oesophageal complications, 751
- oesophageal disorder, 413
- oesophagitis, 567, 577
- oesophagus, 975
- Olithselvan, A., McIntyre, A.S. & Gorard, D.A. Are patients' sedation preferences at gastroscopy influenced by preceding patients' decisions? 989
- Olivero, A. *see* Gaia, S.
- omeprazole, 365, 423, 899, 1171
- on-demand dosing, 181
- on-demand therapy, 389
- on-demand, 657
- onset and disappearance, 803
- Oostenbrug, L.E. *see* Weersma, R.K.
- orally disintegrating tablet, 407
- Orlando, L.A., Kulasingam, S.L. & Matchar, D.B. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography, 1063
- orlistat, 623
- oro-cecal-transit time, 347
- orofacial granulomatosis, 1019
- Osborn, J.F. *see* Gatta, L.
- osteoporosis, 851, 951
- Otsuka, M. *see* Kato, K.
- outcome measure, 891
- Ouyang, H. & Chen, J.D.Z. Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders, 831
- Özgenç, F., Dikici, B. & Yagci, R.V. Letter to the Editors, 247
- Ozturk, R., Niazi, S., Stessman, M. & Rao, S.S.C. Long-term outcome and objective changes of anorectal function after biofeedback therapy for faecal incontinence, 667
- Paganin, S. *see* Gaia, S.
- Pajares, J.M. *see* Gisbert, J.P.
- Palazòn, J.M. *see* Zapater, P.
- Palsson, O.S. *see* Whitehead, W.E.
- pancreas, 983
- pancreatic malignancy, 1063
- pancreatitis, 173, 843
- pantoprazole, 567, 1105
- Paoluzi, O.A. *see* Consolazio, A.
- Paoluzi, P. *see* Consolazio, A.
- paracetamol, 173
- Parente, F., Sampietro, G.M., Molteni, M., Greco, S., Anderloni, A., Sposito, C., Danelli, P.G., Taschieri, A.M., Gallus, S. & Bianchi Porro, G. Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn's disease: a prospective study, 959
- Paris, F. *see* Pilotto, A.
- Partington, S. *see* Guda, N.
- Pascual, S. *see* Zapater, P.
- Peck-Radosavljevic, M. *see* Homoncik, M.
- pegylated interferon- α , 37, 129
- Peine, C. *see* Sacian, K.
- Pelckmans, P. *see* Franchimont, N.
- pellets, 347
- Pellisè, M. *see* Mata, A.
- peptic ulcer, 99, 577, 1091
- percutaneous endoscopic gastrostomy tube, 875
- Pérez-Mateo, M. *see* Zapater, P.
- Perna, F. *see* Gatta, L.
- Perri, F. *see* Annese, V.
- Perrillo, R.P. *see* Nair, S.
- Petereit, H.-U. *see* Bott, C.
- Peters, F.T.M. *see* Weersma, R.K.
- Pettengell, K., Mynhardt, J., Kluyts, T., Lau, W., Facklam, D. & Buell, D. the FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent, 475
- pH monitoring, 423, 559
- pharmacodynamics, 399, 825, 883
- pharmacogenetics, 593
- pharmacokinetics, 29, 223, 399, 825, 859
- pH-dependent delivery, 347
- photodynamic therapy, 1125
- physician-patient correlation, 1161
- Piepoli, A. *see* Annese, V.
- Pierik, M., Vermeire, S., Steen, K.V., Joossens, S., Claessens, G., Vlietinck, R. & Rutgeerts, P. Tumour necrosis factor- α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab, 303
- Pilmer, B.L. *see* Kovacs, T.O.G.
- Pilotto, A., Franceschi, M., Leandro, G., Paris, F., Cascavilla, L., Longo, M.G., Niro, V., Andriulli, A., Scarcelli, C. & Di Mario, F. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs, 1091
- Piqué, J.M. *see* Mata, A.
- placebo, 365, 423
- platelet counts, 437
- platelet reactivity, 437
- pleurodesis, 271
- Ploeg, R.J. *see* Weersma, R.K.
- PMMA, 37
- pneumatic dilatation, 431
- Pockros, P.J. *see* Aspinall, R.J.

- poisoning, 173
 Polito, G. *see* Bruzzese, E.
 Poloniecki, J. *see* Davis, K.J.
 polyethylene glycol (PEG), 825
 polymethacrylates, 347
 polyurethane, 875
 population based, 483
 porfimer sodium, 1125
 portal hypertension, 29, 271
 Porter, S. *see* Leão, J.C.
 positron emission tomography, 1063
 Posthumus, M.D. *see* Weersma, R.K.
 Poulain, D. *see* Annese, V.
 Poves-Francés, C. *see* Rey, E.
 Prebis, M. *see* Getachew, Y.
 prednisolone, 951
 preference measures, 1161
 preneoplastic lesions, 261
 prevalence, 719
 primary biliary cirrhosis, 551
 primary care, 451
 primary sclerosing cholangitis, 943
 Probert, C.S.J. *see* Tobias, J.H.
 probiotics, 813, 1181
 prokinetic drugs, 333
 Proskin, H.M. *see* Rodriguez-Stanley, S.
 prospective, 167
 proton pump inhibition, 195
 proton pump inhibitor therapy, 637
 proton pump inhibitors, 117, 365, 389, 413, 423, 567, 733, 1091, 1171
 psychological general well being, 761, 891
 psychological support counseling, 777
 push enteroscopy, 189
 Putzeys, V. *see* Franchimont, N.
- QoLRAD, 1161
 quadruple therapy, 1071
 quality of life, 167, 803, 1153
 questionnaire, 355, 551
 Quiroga, J.A. *see* Barril, G.
- Rabeneck, L., Davila, J.A., Thompson, M. & El-Serag, H.B.
 Outcomes in elderly patients following surgery for colorectal cancer in the veterans affairs health care system, 1115
 rabeprazole, 181, 451, 899
 Raedler, A., Behrens, C. & Bias, P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trial, 1353
 Raghunath, A.S., Hungin, A.P.S., Wooff, D. & Childs, S.
 Systematic review: the effect of *Helicobacter pylori* and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis, 733
 Raia, V. *see* Bruzzese, E.
 Ramirez, F.C., Holland, J.F., Harker, J. & Leung, F.W.
 Effect of acid on duodenal blood flow and mucus secretion measured by reflectance spectrophotometry: a prospective, randomized-controlled study, 517
 randomized controlled trial, 437, 527
 randomized placebo-controlled trial, 1133
 randomized trial, 365, 423
 randomized, 295
 ranitidine effervescent, 683
 Rao, S.S.C. *see* Ozturk, R.
 Rayner, C.K., Hart, A.L., Hayward, C.M.M., Emmanuel, A.V. & Kamm, M.A. Azathioprine dose escalation in inflammatory bowel disease, 65
 receptors, 237
 rectum, 689
 Reddy, K.R. *see* Campbell, M.S.
 Reed, M.W.R. *see* Kelly, C.J.
 reflectance spectrophotometry, 517
 reflux oesophagitis, 705, 719
 reflux symptoms, 389
 reflux, 497
 regurgitation, 451, 705, 1105
 Reichling, J. *see* Melzer, J.
 Reilly, M.C., Bracco, A., Ricci, J.-F., Santoro, J. & Stevens, T. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAI-IBS), 459
 relative risk, 931
 reliability, 891
 reproducibility, 365
 ReQuest™, 891
 resistance, 675
 response, 365
 retreatment, 213
 review, 1001
 Rey, E., Poves-Francés, C., Sánchez, G., Fueyo, A., Badiola, C. & Díaz-Rubio, M. Effects of effervescent ranitidine on gastric pH: comparison with almagate and placebo in fasting and postprandial conditions, 683
 Reyes, R.S. *see* Feyen, B.
 Reymann, J.M. *see* Siproudhis, L.
 Rhodes, J. *see* Ingram, J.R.
 ribavirin, 129, 917, 1189
 Ricci, C. *see* Gatta, L.
 Ricci, J.-F. *see* Reilly, M.C.
 Richardson, P. *see* Hawkey, C.J.
 Richter, J.E., Fraga, P., Mack, M., Bochenek, W., Sabesin, S.M. & the Pantoprazok US GERD Study Group, Prevention of erosive oesophagitis relapse with pantoprazole, 567
 Rivera, M. *see* Consolazio, A.
 Rizzetto, M. *see* Gaia, S.
 Robaeys, G. *see* Delwaide, J.
 Robinson, M. *see* Gardner, J.D.
 Rocco, A. *see* Nardone, G.
 Rodriguez-Salvanés, F. *see* Barril, G.
 Rodriguez-Stanley, S., Ciociola, A.A., Zubaidi, S., Proskin, H.M. & Miner Jr, P.B. A single dose of ranitidine 150mg modulates oesophageal acid sensitivity in patients with functional heartburn, 975
 Rogers, T. *see* Getachew, Y.
 Röhss, K. *see* Wilder-Smith, C.H.
 Rome classification, 1171
 Rome criteria, 339

- Rösch, W. *see* Melzer, J.
Rosen, J.P. *see* Tsai, H.H.
Ross, D. *see* Fallone, C.A.
van Rossum, L.G.M. *see* Bovenschen, H.J.
Rothenberg, M.E. *see* Hogan, S.P.
Round, P. *see* Winter, T.A.
Routledge, P. *see* Ingram, J.R.
Rubenstein, J.H. & Laine, L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs, 373
Rudolph, M.W. *see* Bott, C.
Ruggero, S. *see* Briani, C.
Ruigómez, A., García Rodríguez, L.A., Wallander, M.-A., Johansson, S., Graffner, H. & Dent, J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice, 751
Ruiz, R. *see* Domènech, E.
Rumi, M.A.K. *see* Amano, Y.
Russel, M.G.V.M. *see* Ryan, B.M.
Russel, M.G.V.M. *see* Wolters, F.L.
Russo, A., Stevens, J.E., Giles, N., Krause, G., O'Donovan, D.G., Horowitz, M. & Jones, K.L. Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis, 333
Rutgeerts, P. *see* Franchimont, N.
Rutgeerts, P. *see* Pierik, M.
Ryan, B.M., Russel, M.G.V.M., Schurgers, L., Wichers, M., Sijbrandij, J., Stockbrugger, R.W. & Schoon, E. Effect of antitumour necrosis factor- α therapy on bone turnover in patients with active Crohn's disease: a prospective study, 851
Ryder, S.D. *see* Boulton-Jones, J.R.
Sabesin, S.M. *see* Richter, J.E.
Saeian, K., Bajaj, J.S., Franco, J., Knox, J.F., Daniel, J., Peine, C., McKee, D., Varma, R.R., Ho, S. & and Midwest Hepatitis Study Group. High-dose vitamin E supplementation does not diminish ribavirin-associated haemolysis in hepatitis C treatment with combination standard α -interferon and ribavirin, 1189
safety, 51, 783
Salgueiro, J., Zubillaga, M., Goldman, C., Barrado, A., Martinez Sarasague, M., Leonardi, N. & Boccio, J. Review article: is there a link between micronutrient malnutrition and *Helicobacter pylori* infection? 1029
Saller, R. *see* Melzer, J.
Salvatori, J.J. *see* Sterling, R.K.
Sampietro, G.M. *see* Parente, F.
Sánchez, G. *see* Rey, E.
Santoro, J. *see* Reilly, M.C.
Sanyal, A.J. *see* Sterling, R.K.
Sanz, P. *see* Barril, G.
Saro, C. *see* Domènech, E.
Sasi, M.R. *see* Tobias, J.H.
satisfaction, 657
de Saussure, P., Laverigne-Slove, A., Mazeron, M.-C., Alain, S., Matuchansky, C. & Bouhnik, Y. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease, 1323
Savarino, V. *see* Frazzoni, M.
scale, 891
Scarcelli, C. *see* Pilotto, A.
Schaffalitzky de Muckadell, O.B. *see* Lassen, A.
Schirmacher, S. *see* Bott, C.
Schmid, M. *see* Homoncik, M.
Schmidt, L.E. & Dalhoff, K. Hyperamylasaemia and acute pancreatitis in paracetamol poisoning, 173
Schneider, A.R.J. *see* Bott, C.
Schoon, E. *see* Ryan, B.M.
Schröder, O., Naumann, M. & Stein, J. Anti-*Saccharomyces cerevisiae* antibodies and response to infliximab in refractory Crohn's disease, 821
Schünemann, H.J. *see* Fallone, C.A.
Schurgers, L. *see* Ryan, B.M.
Schwartz, H. *see* Vakil, N.
Scott, B.B. *see* Bebb, J.R.
Scott, R.J. *see* Koch, K.M.
screening, 1, 507
Scully, C. *see* Leão, J.C.
Sébille, V. *see* Siproudhis, L.
secondary care, 451
sedation, 989
Seide, B.M. *see* Bharucha, A.E.
Selgas, R. *see* Barril, G.
sensation, 831
sensitivity, 975
Servais, B. *see* Delwaide, J.
severity, 355
Shabat-Sehayek, V. *see* Levine, A.
Shapiro, D. *see* Winter, J.
Shepherd, A. *see* Tsai, H.H.
Sherman, J.M. *see* Konstan, M.W.
Sherman, K.E. *see* Neff, G.W.
Shevah, O. *see* Levine, A.
Shiffman, M.L. *see* Sterling, R.K.
Shirin, H. *see* Levine, A.
Shlomi, I. *see* Eliakim, R.
Short, G. *see* Bardhan, K.D.
Siciliano, M. *see* Annicchiaroco, B.E.
side effects, 843, 1181
Sijbrandij, J. *see* Ryan, B.M.
silicone, 875
single subject trials, 365, 423
Siproudhis, L., Dinasquet, M., Sébille, V., Reymann, J.M. & Bellissant, E. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception, 689
site specific delivery, 347
Skalsky, B. *see* Bott, C.
sleep disorders, 1153
sleep, 969
Sloan, S. *see* Gardner, J.D.
Smedile, A. *see* Gaia, S.
Smith, C. *see* West, J.
Smout, A.J.P.M. *see* de Wit, N.J.
Sonnenberg, A. Personal view: 'Don't ask, don't tell' – the undesirable consequences of incidental test results in gastroenterology, 381
Sonnenberg, A. Personal view: cost and benefit of medical rituals in gastroenterology, 939

- Sörberg, M. *see* Tindberg, Y.
 Sostek, M.B. *see* Katz, P.O.
 Spechler's disease activity index, 761
 sphincter repair, 539
 spontaneous bacterial empyema, 271
 Spooner, R.J. *see* Winter, J.
 Sposito, C. *see* Parente, F.
 standard gamble, 1161
 Stanescu, L. *see* Bruley des Varannes, S.
 Stanghellini, V. *see* Bardhan, K.D.
 state anxiety, 777
 Stead, A.G. *see* Koch, K.M.
 Steen, K.V. *see* Pierik, M.
 Stein, J. *see* Bott, C.
 Stein, J. *see* Schröder, O.
 Stenson, W.F. *see* Goldstein, J.L.
 Stephenson, T.J. *see* Kelty, C.J.
 Sterling, R.K., Salvatori, J.J., Luketic, V.A., Sanyal, A.J., Fulcher, A.S., Stravitz, R.T., Contos, M.J., Mills, A.S. & Shiffman, M.L. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis, 943
 Stern, R.C. *see* Konstan, M.W.
 steroid dependency, 161
 steroids, 143, 151
 Stessman, M. *see* Ozturk, R.
 Stevens, J.E. *see* Russo, A.
 Stevens, T. *see* Reilly, M.C.
 Stevens, T., Achkar, J.P., Easley, K., Brzezinski, A. & Lashner, B. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease, 601
 Stockbrugger, R.W. *see* Ryan, B.M.
 Stockbrügger, R.W. *see* Wolters, F.L.
 Stoddard, C.J. *see* Kelty, C.J.
 stool antigen test, 469
 Stravitz, R.T. *see* Sterling, R.K.
 stroke, 73
 Such, J. *see* Zapater, P.
 Sugitani, M. *see* Kato, K.
 Suissa, A. *see* Eliakim, R.
 Sung, J.J.-Y. *see* Wong, V.W.-S.
 Sung, J.J.Y., Leung, W.K., Ching, J.Y.L., Lao, L., Zhang, G., Wu, J.C.Y., Liang, S.M., Xie, H., Ho, Y.P., Chan, L.S., Berman, B. & Chan, F.K.L. Agreements among traditional Chinese medicine practitioners in the diagnosis and treatment of irritable bowel syndrome, 1205
 supply and demand, 507
 surgery, 1115
 survey, 551
 sustained virological response, 931
 Sutherland, M. *see* Blacka, J.
 Suzuki, H. *see* Suzuki, M.
 Suzuki, K. *see* Suzuki, M.
 Suzuki, M., Maruyama, K., Suzuki, H., Tanaki, S., Suzuki, K. & Ishii, H. ¹³C-ethanol breath test reveals impaired alcohol metabolism in patients with *Helicobacter pylori* infection, 109
 Svedberg, L.-E. *see* Wilder-Smith, C.H.
 Symmons, D. *see* Forrest, K.
 symptom assessment, 891
 symptomatic postoperative recurrence, 959
 symptoms, 1105
 systematic review, 373, 733
 Szilagyi, A. *see* Fallone, C.A.
 Tabangin, M. *see* Chand, N.
 Takahashi, D. *see* Yamamoto, T.
 Takahashi, Y. *see* Amano, Y.
 Talley, N.J. *see* Armstrong, D.
 Talley, N.J. *see* Eslick, G.D.
 Talley, N.J. *see* Nandurkar, S.
 Tampieri, A. *see* Gatta, L.
 Tan, A.C.I.T.L. *see* Bovenschen, H.J.
 Tanaki, S. *see* Suzuki, M.
 Tanser, L. *see* Fallone, C.A.
 Taschieri, A.M. *see* Parente, F.
 tegaserod, 213
 Thabane, M. *see* Marshall, J.K.
 therapeutic thoracentesis, 271
 Thomas, G.A.O. *see* Ingram, J.R.
 Thompson, M. *see* Rabeneck, L.
 threshold analysis, 939
 thrombocytopenia, 917
 van Tilburg, A.J.P. *see* West, R.L.
 Tindberg, Y., Casswall, T.H., Blennow, M., Bengtsson, C., Granström, M. & Sörberg, M. *Helicobacter pylori* eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial, 295
 TNF- α , 289
 Tobias, J.H., Sasi, M.R., Greenwood, R. & Probert, C.S.J. Rapid hip bone loss in active Crohn's disease patients receiving short-term corticosteroid therapy, 951
 Toffanin, E. *see* Briani, C.
 tolerance phenomenon, 559
 Torgerson, S. *see* Harrison, S.A.
 toxic hepatitis, 373
 traditional Chinese medicine, 1205
 transjugular intrahepatic portosystemic shunt, 271, 867
 treatment response, 891
 treatment with lamivudine, 281
 treatment, 15, 295
 Triadafilopoulos, G. *see* Gerson, L.B.
 trial design, 423
 Trojan, J. *see* Kerber, A.
 Trout, J.R. *see* Konstan, M.W.
 Tsai, H.H., Chapman, R., Shepherd, A., McKeith, D., Anderson, M., Vearer, D., Duggan, S. & Rosen, J.P. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study, 657
 Tseng, H.-H. *see* Chen, A.
 Tsibouris, P., Hendrickse, M.T. & Isaacs, P.E.T. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma, 645

- tube failure, 875
 tumor marker, 983
 Tunturi-Hihnala, H. see Armstrong, D.
 Turner, M. see Whitehead, W.E.
 Tytgat, G.N.J. see de Wit, N.J.
- ulcer complications, 527
 ulcerative colitis, 143, 161, 1133, 1143
 Ullah, N. see Gerson, L.B.
 Umegae, S. see Yamamoto, T.
 Umesaki, Y. see Kato, K.
 urea breath test, 117, 1001
 ursodeoxycholic acid, 943
 utilities, 1161
- vaccine, 1053
 Vaira, D. see Gatta, L.
 Vakil, N. see Guda, N.
 Vakil, N., Lanza, F., Schwartz, H. & Barth, J. Seven-day therapy for *Helicobacter pylori* in the United States, 99
 valdecoxib, 527
 validity, 891
 Van Gossum, A. see Franchimont, N.
 Van Gossum, M. see Delwaide, J.
 Van Vlierberghe, H. see Delwaide, J.
 Vandewalle, P. see Annese, V.
 Vandvik, P.O., Wilhelmsen, I., Ihlebaek, C. & Farup, P.G.
 Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications, 1195
 Varma, R.R. see Saeian, K.
 vascular disease, 73
 Vearer, D. see Tsai, H.H.
 Venables, T. see Armstrong, D.
 Verburg, K.M. see Goldstein, J.L.
 Vermeire, S. see Franchimont, N.
 Vermeire, S. see Pierik, M.
 Verspaget, H.W. see Gao, Q.
 veteran, 629
 Vijan, S., Inadomi, J., Hayward, R.A., Hofer, T.P. & Fendrick, A.M.
 Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States, 507
 viral kinetics, 825
 viramidine, 917
 visceral sensitivity, 89
 visual analogue scale, 1161
 vitamin E, 1189
 vitamins, 1029
 Vlietinck, R. see Pierik, M.
 volume of distribution, 825
 Von Korf, M. see Whitehead, W.E.
- Wagener, J.S. see Konstan, M.W.
 Wain, E. see Delwaide, J.
 Wakil, G. see Fallone, C.A.
 Walker, A. see Winter, J.
 Wall, G.C. see Feyen, B.
 Wallace, M.B. see Wolfson, H.C.
 Wallander, M.-A. see Ruigómez, A.
 Wallin, L. see Madsen, L.G.
 Wang, J.D. see Gu, Q.
 Wang, W.H. see Gu, Q.
 Ware, J.C. see Chand, N.
 Wassell, J.J. see Dolwani, S.
 Weber, F.T. see Delvaux, M.
 Weersma, R.K., Peters, F.T.M., Oostenbrug, L.E., van den Berg, A.P., van Haastert, M., Ploeg, R.J., Posthumus, M.D., Homan van der Heide, J.J., Jansen, P.L.M. & van Dullemen, H.M.
 Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases, 843
 weight loss, 623
 West, J. see Boulton-Jones, J.R.
 West, J. see Card, T.R.
 West, J., Logan, R.F.A., Card, T.R., Smith, C. & Hubbard, R. Risk of vascular disease in adults with diagnosed coeliac disease: a population-based study, 73
 West, R.L., van der Woude, C.J., Hansen, B.E., Felt-Bersma, R.J.F., van Tilburg, A.J.P., Drapers, J.A.G. & Kuipers, E.J. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study, 1329
 Wheeler, C. see Fallone, C.A.
 Whitehead, W.E., Levy, R.L., Von Korf, M., Feld, A.D., Palsson, O.S., Turner, M. & Drossman, D.A. The usual medical care for irritable bowel syndrome, 1305
 Wichers, M. see Ryan, B.M.
 Wiklund, I. see Fallone, C.A.
 Wiklund, I. see Labus, J.S.
 Wilder-Smith, C.H., Röhss, K., Bondarov, P., Hallerbäck, B., Svedberg, L.-E. & Ahlbom, H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study, 1099
 Wilhelmsen, I. see Vandvik, P.O.
 Winter, J., Walker, A., Shapiro, D., Gaffney, D., Spooner, R.J. & Mills, P.R. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease, 593
 Winter, T.A., Wright, J., Ghosh, S., Jahnson, J., Innes, A. & Round, P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study, 1337
 wireless capsule endoscopy, 189
 Wiseman, M. see Nair, S.
 de Wit, N.J., de Boer, W.A., Geldof, H., Hazelhoff, B., Bergmans, P., Tytgat, G.N.J. & Smout, A.J.P.M. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does *Helicobacter pylori* infection affect proton pump inhibitor effectiveness?, 451
 Witterman, E.M. see Bovenschen, H.J.
 Wohl, M.E.B. see Konstan, M.W.
 Wolfson, H.C., Hemminger, L.L., Wallace, M.B. & DeVault, K.R.
 Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer, 1125
 Wolters, F.L., Russel, M.G.V.M. & Stockbrügger, R.W. Systematic review: has disease outcome in Crohn's disease changed during the last four decades?, 483

- women, 551
- Wong, B.C.-Y. *see* Gu, Q.
- Wong, B.C.Y. *see* Wong, W.M.
- Wong, V.W.-S., Chan, H.L.-Y., Hui, A.Y., Chan, K.-F., Liew, C.-T., Chan, F.K.-L. & Sung, J.J.-Y. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese, 45
- Wong, W.M. *see* Gu, Q.
- Wong, W.M., Lai, K.C., Lam, K.F., Hui, W.M., Huang, J.Q., Xia, H.H.X., Hu, W.H.C., Lam, C.L.K., Chan, C.K., Lam, S.K. & Wong, B.C.Y. Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study, 803
- Wooff, D. *see* Raghunath, A.S.
- work absenteeism, 909
- work productivity, 459
- van der Woude, C.J. *see* West, R.L.
- WPAL, 459
- Wright, J. *see* Winter, T.A.
- Wu, J.C.Y. *see* Sung, J.J.Y.
- Xia, H.H.-X. *see* Gu, Q.
- Xia, H.H.X. *see* Wong, W.M.
- Xie, H. *see* Sung, J.J.Y.
- Yagci, R.V. *see* Özgenc, F.
- Yaghoobi, M. *see* Mikaeli, J.
- Yamada, Y. *see* Yamamoto, T.
- Yamamoto, T., Umegae, S., Kitagawa, T., Yasuda, Y., Yamada, Y., Takahashi, D., Mukumoto, M., Nishimura, N., Yasue, K. & Matsumoto, K. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study, 783
- Yamaoka, Y. *see* Chen, A.
- Yassin, K. *see* Eliakim, R.
- Yasuda, Y. *see* Yamamoto, T.
- Yasue, K. *see* Yamamoto, T.
- YMDD mutants, 281
- Yong, A. *see* Dolwani, S.
- Younger, H.M., Bathgate, A.J. & Hayes, P.C. Review article: nucleoside analogues for the treatment of chronic hepatitis B, 1211
- Yuen, M.F. *see* Gu, Q.
- Yuki, T. *see* Amano, Y.
- van der Zaag-Loonen, H.J. *see* Afzal, N.A.
- van Zanten, S.J.O. *see* Fallone, C.A.
- van Zanten, S.V. *see* Fischbach, L.A.
- Zapater, P., Lasso de la Vega, M.C., Horga, J.F., Such, J., Frances, R., Esteban, A., Palazón, J.M., Carnicer, F., Pascual, S. & Pérez-Mateo, M. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status, 29
- Zara, G. *see* Briani, C.
- Zelmac/Zelnorm, 213
- Zentilin, P. *see* Frazzoni, M.
- Zgouras, D. *see* Kerber, A.
- Zhang, G. *see* Sung, J.J.Y.
- Zimmerman, J. Irritable bowel, smoking and oesophageal acid exposure: an insight into the nature of symptoms of gastro-oesophageal reflux, 1297
- Zinsmeister, A.R. *see* Bharucha, A.E.
- Zinsmeister, A.R. *see* Nandurkar, S.
- Zocco, M.A. *see* Nista, E.C.
- Zubaidi, S. *see* Rodriguez-Stanley, S.
- Zubillaga, M. *see* Salgueiro, J.

